Hypercholesterolemia Treatment Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Hypercholesterolemia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (Genetic Hypercholesterolemia, Acquired Hypercholesterolemia), By Treatment Type (Statins, PCSK9 Inhibitors, Ezetimibe, Bile Acid Sequestrants, Niacin, Bempedoic Acid, Others), By End User (Hospitals, Specialty Cardiac Centers, Others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Hypercholesterolemia Treatment Market is projected to expand significantly, rising from USD 21.13 Million in 2025 to USD 33.51 Million by 2031, demonstrating a robust 7.99% CAGR. This growth is driven by the escalating global burden of cardiovascular diseases and an aging population necessitating consistent, long-term lipid management, with treatments encompassing pharmaceutical and medical interventions aimed at reducing elevated LDL cholesterol and preventing atherosclerosis progression. For instance, the American Heart Association estimated approximately 612 million cases of cardiovascular disease globally in 2025, underscoring the critical need for effective therapies.
Market Driver
A primary catalyst for this market expansion is the continuous advancement in novel lipid-lowering therapeutics and drug delivery systems, moving beyond traditional statins to innovative biologic solutions such as PCSK9 inhibitors and siRNA therapies. These advanced formulations address unmet patient needs, particularly for those with statin intolerance or requiring substantial LDL reduction, while improving adherence through less frequent dosing. This is evident in the rapid market uptake, with Novartis reporting Leqvio sales growth of 119% year-over-year to USD 198 million in Q3 2024, and Amgen noting a 40% increase in Repatha revenue to USD 567 million, primarily due to volume growth, in Q3 2024. The fundamental demand also stems from the increasing global prevalence of cardiovascular diseases and dyslipidemia, which mandates aggressive pharmaceutical management to mitigate mortality risks. The American Heart Association reported that approximately 3.72 million global deaths in 2021 were attributed to high LDL cholesterol, reinforcing the urgent clinical imperative for effective therapeutic coverage.
Market Challenge
Despite this growth, a significant challenge impeding market expansion is the prohibitive cost of novel biologic drugs like PCSK9 inhibitors. This financial barrier leads to restrictive reimbursement policies and stringent step-therapy protocols from payers, thereby limiting patient access, reducing long-term adherence, and ultimately compressing potential sales volumes, especially in price-sensitive developing economies. The impact of this restriction is substantial, as clinical data from the American College of Cardiology in 2025 revealed that 60% of high-risk individuals with atherosclerotic cardiovascular disease were not receiving any lipid-lowering therapy, highlighting how affordability and access issues hinder market penetration.
Market Trends
In terms of market trends, there is a notable shift towards Fixed-Dose Combination (FDC) regimens, particularly oral non-statin alternatives, designed to improve adherence for statin-intolerant patients by reducing pill burden and avoiding common side effects. Esperion Therapeutics’ oral non-statin franchise, for example, saw a 53% year-over-year revenue increase to USD 51.6 million in Q3 2024, reflecting strong demand. Concurrently, advancements in gene editing technologies, such as CRISPR base-editing platforms, are revolutionizing the research landscape by exploring potential one-time curative interventions. These technologies aim to permanently inactivate the PCSK9 gene to provide durable therapeutic solutions for severe genetic hypercholesterolemia, moving beyond lifelong dosing schedules. Verve Therapeutics' Heart-1 trial, for instance, demonstrated time-averaged LDL cholesterol reductions of up to 55% with a single infusion of investigational medicine VERVE-101 in patients with heterozygous familial hypercholesterolemia, marking a significant step towards sustained lipid reduction.
Key Market Players
* Novartis AG
* Amgen Inc.
* Sanofi S.A.
* Regeneron Pharmaceuticals, Inc.
* Pfizer Inc.
* Eli Lilly and Company
* Bristol-Myers Squibb Company
* Merck & Co., Inc.
* AstraZeneca plc
* AbbVie Inc.
Report Scope
In this report, the Global Hypercholesterolemia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Hypercholesterolemia Treatment Market, By Disease Type
* Genetic Hypercholesterolemia
* Acquired Hypercholesterolemia
# Hypercholesterolemia Treatment Market, By Treatment Type
* Statins
* PCSK9 Inhibitors
* Ezetimibe
* Bile Acid Sequestrants
* Niacin
* Bempedoic Acid
* Others
# Hypercholesterolemia Treatment Market, By End User
* Hospitals
* Specialty Cardiac Centers
* Others
# Hypercholesterolemia Treatment Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Hypercholesterolemia Treatment Market.
Available Customizations:
Global Hypercholesterolemia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Hypercholesterolemia Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type (Genetic Hypercholesterolemia, Acquired Hypercholesterolemia)
5.2.2. By Treatment Type (Statins, PCSK9 Inhibitors, Ezetimibe, Bile Acid Sequestrants, Niacin, Bempedoic Acid, Others)
5.2.3. By End User (Hospitals, Specialty Cardiac Centers, Others)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Hypercholesterolemia Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Treatment Type
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Hypercholesterolemia Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Treatment Type
6.3.1.2.3. By End User
6.3.2. Canada Hypercholesterolemia Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Treatment Type
6.3.2.2.3. By End User
6.3.3. Mexico Hypercholesterolemia Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Treatment Type
6.3.3.2.3. By End User
7. Europe Hypercholesterolemia Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Treatment Type
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Hypercholesterolemia Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Treatment Type
7.3.1.2.3. By End User
7.3.2. France Hypercholesterolemia Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Treatment Type
7.3.2.2.3. By End User
7.3.3. United Kingdom Hypercholesterolemia Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Treatment Type
7.3.3.2.3. By End User
7.3.4. Italy Hypercholesterolemia Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease Type
7.3.4.2.2. By Treatment Type
7.3.4.2.3. By End User
7.3.5. Spain Hypercholesterolemia Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease Type
7.3.5.2.2. By Treatment Type
7.3.5.2.3. By End User
8. Asia Pacific Hypercholesterolemia Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Treatment Type
8.2.3. By End User
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Hypercholesterolemia Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Treatment Type
8.3.1.2.3. By End User
8.3.2. India Hypercholesterolemia Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Treatment Type
8.3.2.2.3. By End User
8.3.3. Japan Hypercholesterolemia Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Treatment Type
8.3.3.2.3. By End User
8.3.4. South Korea Hypercholesterolemia Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease Type
8.3.4.2.2. By Treatment Type
8.3.4.2.3. By End User
8.3.5. Australia Hypercholesterolemia Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease Type
8.3.5.2.2. By Treatment Type
8.3.5.2.3. By End User
9. Middle East & Africa Hypercholesterolemia Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Treatment Type
9.2.3. By End User
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Hypercholesterolemia Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Treatment Type
9.3.1.2.3. By End User
9.3.2. UAE Hypercholesterolemia Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Treatment Type
9.3.2.2.3. By End User
9.3.3. South Africa Hypercholesterolemia Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Treatment Type
9.3.3.2.3. By End User
10. South America Hypercholesterolemia Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Treatment Type
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Hypercholesterolemia Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease Type
10.3.1.2.2. By Treatment Type
10.3.1.2.3. By End User
10.3.2. Colombia Hypercholesterolemia Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease Type
10.3.2.2.2. By Treatment Type
10.3.2.2.3. By End User
10.3.3. Argentina Hypercholesterolemia Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease Type
10.3.3.2.2. By Treatment Type
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Hypercholesterolemia Treatment Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Novartis AG
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Amgen Inc.
15.3. Sanofi S.A.
15.4. Regeneron Pharmaceuticals, Inc.
15.5. Pfizer Inc.
15.6. Eli Lilly and Company
15.7. Bristol-Myers Squibb Company
15.8. Merck & Co., Inc.
15.9. AstraZeneca plc
15.10. AbbVie Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們